Alleviative effects of Cannabis flower on migraine and headache

Burch, 2015, The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies, Headache, 55, 21, 10.1111/head.12482 Migraine Research Foundation. Migraine facts. (2020-06) [2020-06-08]. https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Finocchi, 2014, Sex-related differences in migraine, Neurol Sci, 35, 207, 10.1007/s10072-014-1772-y Wöber-Bingöl, 2013, Epidemiology of migraine and headache in children and adolescents, Curr Pain Headache Rep, 17, 341, 10.1007/s11916-013-0341-z Kristoffersen, 2019, Illness perception in people with primary and secondary chronic headache in the general population, J Psychosom Res, 116, 83, 10.1016/j.jpsychores.2018.12.001 Minen, 2016, Migraine and its psychiatric comorbidities, J Neurol Neurosurg Psychiatry, 87, 741, 10.1136/jnnp-2015-312233 Lipton, 2015, Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention, Headache, 55, 103, 10.1111/head.12505_2 Ong, 2018, Migraine treatment: current acute medications and their potential mechanisms of action, Neurotherapeutics, 15, 274, 10.1007/s13311-017-0592-1 Harpole, 2005, Burden of illness and satisfaction with care among patients with headache seen in a primary care setting, Headache, 45, 1048, 10.1111/j.1526-4610.2005.05186.x Seng, 2017, Acute migraine medication adherence, migraine disability and patient satisfaction: a naturalistic daily diary study, Cephalalgia, 37, 955, 10.1177/0333102416663459 Andersson, 2017, Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches, Harm Reduct J, 14, 60, 10.1186/s12954-017-0186-6 Bigal, 2007, Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden, Headache, 47, 475, 10.1111/j.1526-4610.2007.00752.x Lee, 2016, Does complementary and alternative medicine (CAM) use reduce negative life impact of headaches for chronic migraineurs? A national survey, Springerplus, 5, 1006, 10.1186/s40064-016-2362-7 Rhee, 2018, Reasons for and perceived benefits of utilizing complementary and alternative medicine in U.S. adults with migraines/severe headaches, Complement Ther Clin Pract, 30, 44, 10.1016/j.ctcp.2017.12.003 Piper, 2017, Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep, J Psychopharmacol, 31, 569, 10.1177/0269881117699616 Vigil, 2017, Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study, PLoS ONE, 12, 1, 10.1371/journal.pone.0187795 Stith, 2018, Effects of legal access to cannabis on scheduled II–V drug prescriptions, J Am Med Dir Assoc, 19, 59, 10.1016/j.jamda.2017.07.017 Baron, 2018, Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort, J Headache Pain, 19, 37, 10.1186/s10194-018-0862-2 Stith, 2016, Federal barriers to cannabis research, Science, 352, 1182, 10.1126/science.aaf7450 National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): National Academies Press (US); 2017. Sexton, 2016, A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy, Cannabis Cannabinoid Res, 1, 131, 10.1089/can.2016.0007 Baron, 2015, Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache, Headache, 55, 885, 10.1111/head.12570 Russo, 2016, Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes, Cannabis Cannabinoid Res, 1, 154, 10.1089/can.2016.0009 Kandasamy, 2018, Anti-migraine effect of Δ9-tetrahydrocannabinol in the female rat, Eur J Pharmacol, 818, 271, 10.1016/j.ejphar.2017.10.054 Rhyne, 2016, Effects of medical marijuana on migraine headache frequency in an adult population, Pharmacotherapy, 36, 505, 10.1002/phar.1673 Americans for Safe Access. Releaf. (2020-06) [2020-06-08]. https://releafapp.com/. Pollio, 2016, The name of Cannabis: a short guide for nonbotanists, Cannabis Cannabinoid Res, 1, 234, 10.1089/can.2016.0027 Lamark J. Encyclopédie Métodique. Botanique. Paris-Liege: Panckouke; 1783–803 [French]. Vigil, 2018, Effectiveness of raw, natural medical Cannabis flower for treating insomnia under naturalistic conditions, Medicines (Basel), 5, 75, 10.3390/medicines5030075 Stith, 2019, The association between cannabis product characteristics and symptom relief, Sci Rep, 9, 2712, 10.1038/s41598-019-39462-1 Montagna, 2008, The primary headaches: genetics, epigenetics and a behavioural genetic model, J Headache Pain, 9, 57, 10.1007/s10194-008-0026-x Schytz, 2017, Challenges in developing drugs for primary headaches, Prog Neurobiol, 152, 70, 10.1016/j.pneurobio.2015.12.005 Beckmann, 2012, Headaches related to psychoactive substance use, Clin Neurol Neurosurg, 114, 990, 10.1016/j.clineuro.2012.02.041 DaSilva, 2017, Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo, Neurology, 88, 1634, 10.1212/WNL.0000000000003861 Peroutka, 1997, Dopamine and migraine, Neurology, 49, 650, 10.1212/WNL.49.3.650 Bloomfield, 2016, The effects of Δ9-tetrahydrocannabinol on the dopamine system, Nature, 539, 369, 10.1038/nature20153 Colizzi, 2016, Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence, Neurosci Biobehav Rev, 64, 359, 10.1016/j.neubiorev.2016.03.010 Jamero, 2011, The emerging role of NMDA antagonists in pain management, US Pharm, 36 Nikolaev, 2012, Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations, Neuropharmacology, 62, 2078, 10.1016/j.neuropharm.2011.12.029 Moisset, 2017, Ketamine infusion combined with magnesium as a therapy for intractable chronic cluster headache: report of two cases, Headache, 57, 1261, 10.1111/head.13135 Longoni, 2006, Inflammation and excitotoxicity: role in migraine pathogenesis, Neurol Sci, 27, S107, 10.1007/s10072-006-0582-2 D’Andrea, 2005, Migraine with aura from pathophysiology to treatment: therapeutic strategies, Neurol Sci, 26, S104, 10.1007/s10072-005-0420-y Borkum, 2016, Migraine triggers and oxidative stress: a narrative review and synthesis, Headache, 56, 12, 10.1111/head.12725 Shen, 2018, Δ9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture, Mol Pharmacol, 55, 8, 10.1124/mol.55.1.8 Gilbert, 2007, Δ9-Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity, Brain Res, 1128, 61, 10.1016/j.brainres.2006.03.011 Russo, 2001, Hemp for headache, J Cannabis Ther, 1, 21, 10.1300/J175v01n02_04 Roloff, 2009, Modulation of excitatory synaptic transmission by Δ9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate, Mol Pharmacol, 75, 892, 10.1124/mol.108.051482 Morera-Herreras, 2010, Two opposite effects of Δ9-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission, Synapse, 64, 20, 10.1002/syn.20701 Karhson, 2016, Endocannabinoid signaling in social functioning: an RDoC perspective, Transl Psychiatry, 6, e905, 10.1038/tp.2016.169 Di Marzo, 2015, Endocannabinoid signaling and the deteriorating brain, Nat Rev Neurosci, 16, 30, 10.1038/nrn3876 Vigil, 2014, No pain, no social gains: a social-signaling perspective of human pain behaviors, World J Anesthesiol, 3, 18, 10.5313/wja.v3.i1.18 Bushlin, 2012, Dimerization with cannabinoid receptors allosterically modulates Δ opioid receptor activity during neuropathic pain, PLoS ONE, 7, e49789, 10.1371/journal.pone.0049789 Dhopeshwarkar, 2014, CB2 Cannabinoid receptors as a therapeutic target—what does the future hold?, Mol Pharmacol, 86, 430, 10.1124/mol.114.094649 Navarro, 2018, Functional interaction between opioid and cannabinoid receptors in drug self-administration, J Neurosci, 21, 5344, 10.1523/JNEUROSCI.21-14-05344.2001 Rios, 2006, μ opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis, Br J Pharmacol, 148, 387, 10.1038/sj.bjp.0706757 Robledo, 2008, Advances in the field of cannabinoid—opioid cross-talk, Addict Biol, 13, 213, 10.1111/j.1369-1600.2008.00107.x Schoffelmeer, 2006, Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core, Neuropharmacology, 51, 773, 10.1016/j.neuropharm.2006.05.019 Meehan-Atrash, 2017, Toxicant formation in dabbing: the terpene story, ACS Omega, 2, 6112, 10.1021/acsomega.7b01130